Max Healthcare Institute Limited (MAXHEALTH) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Max Healthcare Institute is preparing to report its Q1 FY27 results, a pivotal quarter where the company aims to demonstrate the full impact of recent capacity expansions and regulatory tailwinds. Investors will be focused on the margin-accretive potential of newly commissioned brownfield towers and the realization of the full run-rate benefit from the CGHS super-specialty rate revision.
| Results date | August 13, 2026 |
|---|---|
| Quarter | Q1 FY27 |
| Previous quarter revenue | Rs. 2,541 Cr |
| Previous quarter PAT | Rs. 387 Cr |
| Previous quarter EBITDA margin | 26.8% |
| Net debt (latest quarter) | Rs. 1,908 Cr |
| Market cap | Rs. 1,01,122.76 Cr |
| CMP | Rs. 1,040.0 |
Max Healthcare Institute Limited Q1 Results Date and Time
The company will hold a board meeting on August 13, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
An earnings call is scheduled for August 14, 2026, at 11:00 am IST to discuss the Q1 FY27 results.
What to expect from Max Healthcare Institute Limited's Q1 FY27 results
Max Healthcare enters Q1 FY27 with a strong seasonal tailwind as early vector-borne disease trends in Delhi and Karnataka signal an active pre-monsoon hospitalisation environment. The quarter is expected to reflect the full materialisation of the CGHS super-specialty rate revision, with management previously guiding for a net sustained annual margin impact of Rs. 140 Cr.
Operational leverage is anticipated to improve as newly commissioned capacities at Max Smart Saket, Mohali, and Nanavati Max transition from initial ramp-up phases toward higher EBITDA margins. The company's focus remains on integrating the recently acquired Kalinga Hospital while navigating the elevated doctor compensation costs associated with its aggressive 20-25% capacity expansion plan. The upcoming call will likely address the trajectory of oncology OBD volumes following the discontinuation of certain high-value drugs and the impact of new IRDAI cashless-settlement mandates on operational efficiency.
Key Things To Watch
Performance vs Guidance Tracking: Tracking the realization of key financial and operational targets set by management.
- CGHS rate revision — net Rs. 140 Cr sustained margin benefit — full run-rate expected from Q1 FY27
- Bed capacity — target 6,500 beds by end of FY27 — status ahead with >6,000 beds operational as of May 2026
- Net debt-to-EBITDA — target less than 1x — status achieved at 0.93x in Q4 FY26
Capacity Ramp-up Status: Monitoring the operational progress of recent brownfield and M&A additions.
- Max Smart Saket — 156 beds commissioned in April 2026 with phased ramp-up ongoing
- Nanavati Max — 116 of 280 beds operationalized by May 2026
- Kalinga Hospital — first full quarter of contribution following May 2026 acquisition
Risks and headwinds to monitor: Key operational and regulatory challenges impacting the current quarter.
- Oncology OBDs declined 6% YoY in Q4 FY26 due to drug discontinuation; monitoring for volume stabilization
- Direct costs rose to 41.1% of net revenue in Q4 FY26; watching for stabilization via operating leverage
- NCLT litigation regarding Kalinga Hospital acquisition remains ongoing with hearings post-July 2026
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
How much of the CGHS rate revision benefit has already been realized?
As of the Q4 FY26 earnings call, the company had realized Rs. 100-110 Cr of the projected Rs. 200 Cr gross top-line benefit. Management expected the remaining Rs. 30-40 Cr to flow through starting in Q1 FY27.
What is the current status of Max Healthcare's debt?
As of March 31, 2026, the company reported a net debt of Rs. 1,908 Cr. This maintains a net debt-to-EBITDA ratio of below 1.0x.
How do brownfield expansions impact the company's margins?
Management has stated that brownfield capacity should immediately operate at higher EBITDA margins compared to the existing network. This is expected to support overall margin expansion as these new towers fill up.
Related
- Max Healthcare Institute Ltd (MAXHEALTH) Q1 FY27 Results Analysis: EBITDA Margin Compresses 301 bps, Revenue Grows 16.7%Q1 FY2026-2027 Results Analysis
- Max Healthcare Institute Ltd (MAXHEALTH) Q1 FY27 Earnings Call: Medical Education Entry Approved, Sees 20,000-40,000 Bed CeilingQ1 FY2026-2027 Earnings Call
- MAXHEALTH Q4 FY26 Results Analysis: PAT Surges 34%, Margin Expands 151 bpsQ4 FY2025-2026 Analysis
- MAXHEALTH Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To WatchQ4 FY2025-2026 Preview